Status:
UNKNOWN
Safety and Efficacy of Oral Versus Intravenous Amiodarone in the Treatment of AF
Lead Sponsor:
Western Galilee Hospital-Nahariya
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Atrial fibrillation (AF) remains a significant contributor to cardiovascular morbidity. Amiodarone is a potent antiarrhythmic drug; however, patients receiving IV amiodarone are at high risk for phleb...
Detailed Description
Atrial fibrillation (AF) is the most common heart rhythm abnormality worldwide. Three therapeutic goals should be considered for each patient: Rate control, maintenance of sinus rhythm and prevention ...
Eligibility Criteria
Inclusion
- Over 18 years of age,
- Patients who will be admitted to the ICCU / ICU wards
- Patients with recent onset of atrial fibrillation (duration \< 48h).
Exclusion
- Age \< 18 years
- Baseline systolic blood pressure \< 100 mm/hg
- Known thyroid disease
- Serum potassium \< 3.5 mmol/l
- Pretreatment with amiodarone
- Pregnant or lactating women.
- Participation in other clinical trial.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2015
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT01817439
Start Date
May 1 2013
End Date
May 1 2015
Last Update
March 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Western Galilee Hospital
Nahariya, Israel, Israel, 972